Members Login
Username 
 
Password 
    Remember Me  
Post Info TOPIC: Meningococcal Vaccines Market Overview Market Size, Share, Growth, Competitive Insight And Key Drivers, Research Report


Senior Member

Status: Offline
Posts: 477
Date:
Meningococcal Vaccines Market Overview Market Size, Share, Growth, Competitive Insight And Key Drivers, Research Report
Permalink   


Market Synopsis

As per the research conducted by Market Research Future (MRFR), Meningococcal Vaccines Market Overview size is projected to be worth USD 5.91 billion by 2030, registering a CAGR of 7.29% during the forecast period (2022 - 2030),

The growing adoption of vaccination to eliminate bacterial meningitis is expected to increase the demand for immunization therapies, which can augment the global market in the assessment period. The growing initiatives by the government and various authorities to counter the increasing prevalence of meningitis is likely to offer efficient methods of immunization, which is predicted to strengthen the industry. Furthermore, the surging funds for R&D are projected to combat the increasing cases of meningococcal infection that is likely to offer lucrative opportunities to vaccine manufacturing companies, which can boost the trade.

On the other hand, stringent government regulations for the approval of the new vaccines are likely to hamper the market in the coming period. However, effective meningococcal vaccination programs and the rising healthcare expenses can counter the impeding cause that can boost the market growth during the forecast period.

Key Players

Eminent players of the global market for meningococcal vaccine market are Serum Institute of India Ltd., Pfizer Inc., Baxter International, Novartis Pharmaceuticals Canada Inc, JN-International Medical Corporation, Sanofi S.A., Biomed Pvt. Ltd., and GlaxoSmithKline, among others.

Market Segmentation

The segmental analysis of the global market for meningococcal vaccines is done by end-user and treatment type.

·         The end-user segments of the global market for meningococcal vaccines are research & academic institutes, hospitals & clinics, and others.

·         The treatment-type segments of the global market for meningococcal vaccines are polysaccharides, meningococcal conjugate vaccine, and subcapsular vaccine.

Regional Analysis

On the basis of region, the global market for meningococcal vaccines is segmented into North America, Europe, Asia-Pacific, and the Rest of the World (RoW).

The global market is anticipated to be dominated by North America during the forecast period due to the growing support from the government of various regions. High investments in R&D are predicted to be another significant cause that can strengthen the regional market during the forecast period. Among all, the US is projected to make the most significant contribution in developing vaccines owing to the increasing incidence of meningococcal diseases.

Europe is anticipated to acquire a significant market value during the forecast period owing to the increasing research in the concerned field. Furthermore, the growing favorable initiatives taken by the government of various countries of the region are recognized to be another salient cause that can develop the regional market in the coming period.

APAC is expected to grow at a significant rate during the review period owing to the increasing incidence of meningococcal diseases. Therefore, there has been a rise in the production of the vaccine. The growing pediatric population and the rising initiatives taken by the government of various countries to combat the diseases are projected to augment the regional market during the review period.

MEA is expected to acquire a small market share during the forecast period owing to high prices of the vaccine and limited availability. The MEA countries have expressed interest in introducing a multivalent and conjugate vaccine into the National Immunization Program Schedule but have failed to do so owing to the prevailing economic crisis among the countries.

Industry News

·         November 2020

A renowned French pharma company, Sanofi, has received approval from the European Commission for its Meningococcal (MenACWY) vaccine MenQuadfi. The EC has given conformity for immunizing the individuals from the age of 12 months and older.

Related Report-

·         Hearing Aids Market Research Report - Global Forecast till 2027

·         Patient Engagement Solutions Market Research Report - Global Forecast till 2027            

About US:

Market Research Future (MRFR) enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street,5Th Floor, New York,

New York 10013

 

 

 

 

 



__________________
Page 1 of 1  sorted by
Quick Reply

Please log in to post quick replies.

Tweet this page Post to Digg Post to Del.icio.us


Create your own FREE Forum
Report Abuse
Powered by ActiveBoard